Sin embargo, el informe puede estar disponible en español por un costo adicional.
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
5 Global Biopharmaceutical Market
5.1 Market Performance and Forecast
5.1.1 Current Performance (2018-2023)
5.1.2 Market Forecast (2024-2032)
5.2 Impact of COVID-19
5.3 Market by Region
5.3.1 Current Performance (2018-2023)
5.3.2 Market Forecast (2024-2032)
5.4 Market by Indication
5.4.1 Autoimmune Diseases
5.4.2 Oncology
5.4.3 Metabolic Disorders
5.4.4 Others
5.5 Market by Class
5.5.1 Recombinant Proteins
5.5.1.1 Current Performance (2018-2023)
5.5.1.2 Market Forecast (2024-2032)
5.5.2 Monoclonal Antibodies
5.5.2.1 Current Performance (2018-2023)
5.5.2.2 Market Forecast (2024-2032)
5.5.3 Purified Proteins
5.5.3.1 Current Performance (2018-2023)
5.5.3.2 Market Forecast (2024-2032)
5.6 Competitive Landscape
5.6.1 Top Biopharmaceutical Players
5.6.2 Top Biopharmaceutical Drugs
5.7 Value Chain Analysis
5.8 Porter’s Five Forces Analysis
5.8.1 Overview
5.8.2 Bargaining Power of Buyers
5.8.3 Bargaining Power of Suppliers
5.8.4 Degree of Rivalry
5.8.5 Threat of New Entrants
5.8.6 Threat of Substitutes
6 North America
6.1 United States
6.1.1 Market Performance (2018-2023)
6.1.2 Market by Class
6.1.2.1 Recombinant Proteins
6.1.2.2 Monoclonal Antibodies
6.1.2.3 Purified Proteins
6.1.3 Top Players
6.1.4 Market Forecast (2024-2032)
6.2 Canada
6.2.1 Market Performance (2018-2023)
6.2.2 Market by Class
6.2.2.1 Recombinant Proteins
6.2.2.2 Monoclonal Antibodies
6.2.2.3 Purified Proteins
6.2.3 Top Players
6.2.4 Market Forecast (2024-2032)
7 Latin America
7.1 Mexico
7.1.1 Market Performance (2018-2023)
7.1.2 Market by Class
7.1.2.1 Recombinant Proteins
7.1.2.2 Monoclonal Antibodies
7.1.2.3 Purified Proteins
7.1.3 Top Players
7.1.4 Market Forecast (2024-2032)
7.2 Brazil
7.2.1 Market Performance (2018-2023)
7.2.2 Market by Class
7.2.2.1 Recombinant Proteins
7.2.2.2 Monoclonal Antibodies
7.2.2.3 Purified Proteins
7.2.3 Top Players
7.2.4 Market Forecast (2024-2032)
7.3 Argentina
7.3.1 Market Performance (2018-2023)
7.3.2 Market by Class
7.3.2.1 Recombinant Proteins
7.3.2.2 Monoclonal Antibodies
7.3.2.3 Purified Proteins
7.3.3 Top Players
7.3.4 Market Forecast (2024-2032)
8 Europe
8.1 Germany
8.1.1 Market Performance (2018-2023)
8.1.2 Market by Class
8.1.2.1 Recombinant Proteins
8.1.2.2 Monoclonal Antibodies
8.1.2.3 Purified Proteins
8.1.3 Top Players
8.1.4 Market Forecast (2024-2032)
8.2 France
8.2.1 Market Performance (2018-2023)
8.2.2 Market by Class
8.2.2.1 Recombinant Proteins
8.2.2.2 Monoclonal Antibodies
8.2.2.3 Purified Proteins
8.2.3 Top Players
8.2.4 Market Forecast (2024-2032)
8.3 Italy
8.3.1 Market Performance (2018-2023)
8.3.2 Market by Class
8.3.2.1 Recombinant Proteins
8.3.2.2 Monoclonal Antibodies
8.3.2.3 Purified Proteins
8.3.3 Top Players
8.3.4 Market Forecast (2024-2032)
8.4 Spain
8.4.1 Market Performance (2018-2023)
8.4.2 Market by Class
8.4.2.1 Recombinant Proteins
8.4.2.2 Monoclonal Antibodies
8.4.2.3 Purified Proteins
8.4.3 Top Players
8.4.4 Market Forecast (2024-2032)
8.5 United Kingdom
8.5.1 Market Performance (2018-2023)
8.5.2 Market by Class
8.5.2.1 Recombinant Proteins
8.5.2.2 Monoclonal Antibodies
8.5.2.3 Purified Proteins
8.5.3 Top Players
8.5.4 Market Forecast (2024-2032)
8.6 Russia
8.6.1 Market Performance (2018-2023)
8.6.2 Market by Class
8.6.2.1 Recombinant Proteins
8.6.2.2 Monoclonal Antibodies
8.6.2.3 Purified Proteins
8.6.3 Top Players
8.6.4 Market Forecast (2024-2032)
8.7 Turkey
8.7.1 Market Performance (2018-2023)
8.7.2 Market by Class
8.7.2.1 Recombinant Proteins
8.7.2.2 Monoclonal Antibodies
8.7.2.3 Purified Proteins
8.7.3 Top Players
8.7.4 Market Forecast (2024-2032)
9 Asia Pacific
9.1 Japan
9.1.1 Market Performance (2018-2023)
9.1.2 Market by Class
9.1.2.1 Recombinant Proteins
9.1.2.2 Monoclonal Antibodies
9.1.2.3 Purified Proteins
9.1.3 Top Players
9.1.4 Market Forecast (2024-2032)
9.2 China
9.2.1 Market Performance (2018-2023)
9.2.2 Market by Class
9.2.2.1 Recombinant Proteins
9.2.2.2 Monoclonal Antibodies
9.2.2.3 Purified Proteins
9.2.3 Top Players
9.2.4 Market Forecast (2024-2032)
9.3 Australia
9.3.1 Market Performance (2018-2023)
9.3.2 Market by Class
9.3.2.1 Recombinant Proteins
9.3.2.2 Monoclonal Antibodies
9.3.2.3 Purified Proteins
9.3.3 Top Players
9.3.4 Market Forecast (2024-2032)
9.4 South Korea
9.4.1 Market Performance (2018-2023)
9.4.1.1 Recombinant Proteins
9.4.1.2 Monoclonal Antibodies
9.4.1.3 Purified Proteins
9.4.2 Top Players
9.4.3 Market Forecast (2024-2032)
9.5 India
9.5.1 Market Performance (2018-2023)
9.5.2 Market by Class
9.5.2.1 Recombinant Proteins
9.5.2.2 Monoclonal Antibodies
9.5.2.3 Purified Proteins
9.5.3 Top Players
9.5.4 Market Forecast (2024-2032)
9.6 Indonesia
9.6.1 Market Performance (2018-2023)
9.6.2 Market by Class
9.6.2.1 Recombinant Proteins
9.6.2.2 Monoclonal Antibodies
9.6.2.3 Purified Proteins
9.6.3 Top Players
9.6.4 Market Forecast (2024-2032)
10 SWOT Analysis
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 Competitive Landscape
11.1 Market Structure
11.2 Key Players
11.3 Profiles of Key Players
11.3.1 AbbVie Inc.
11.3.2 Amgen Inc
11.3.3 Biogen Inc.
11.3.4 Eli Lilly and Company
11.3.5 F. Hoffmann-La Roche AG
11.3.6 Johnson & Johnson
11.3.7 Merck & Co. Inc.
11.3.8 Novo Nordisk A/S
11.3.9 Pfizer Inc.
11.3.10 Sanofi S.A